Take this short 5-question quiz to find out what you know--or, what you may have missed--about the latest developments in COPD.
New Drug Boosts COPD Lung Function, QoL Regardless of Severity: Daily Dose
Your daily dose of the clinical news you may have missed.
Single vs Multiple Inhaler Triple Therapy for COPD Could Triple Adherence, Persistence: International Data
CHEST 2024: Combined data from 4 continents found consistently better adherence/persistence when COPD triple therapy was initiated with a single inhaler.
Early Identification, Treatment of COPD Reduces Exacerbations, Health Care Burden
CHEST 2024. Initial treatment for people with COPD should begin early in the disease and leads to significantly reduced risk for exacerbations and inpatient treatment.
Ensifentrine, Novel PDE3, PDE4 Inhibitor, Improves Lung Function, QoL Regardless of COPD Severity
The combined bronchodilator/anti-inflammatory agent significantly improved lung function, symptoms and QoL in adults with moderate or severe airflow obstruction.
FDA Approves First-Ever Biologic Medicine for COPD: Daily Dose
Dupilumab Becomes First Biologic Approved in the US as Targeted Therapy for Adults with COPD
Dupilumab represents the first new treatment approach for uncontrolled COPD in more than a decade and reduced disease exacerbations by 34% in clinical trials.